Literature DB >> 20959326

State-of-the-art: rheumatoid arthritis.

Iain B McInnes1, James R O'Dell.   

Abstract

The understanding of the pathogenesis and optimal therapeutics for rheumatoid arthritis (RA) has advanced remarkably over the last decade. This review highlights these key advances, particularly the outcomes of genome-wide scans which have provided an increasingly robust appraisal of the complex genetics that underpin RA. Such observations are placed in pathogenetic context, particularly concerning the breach of tolerance that presages synovitis and the mechanisms that subserve chronicity. The key therapeutic strategies and treatment agents, both conventional and biological, now available to effectively manage the disease are described. Throughout the review, emphasis is placed on unanswered questions and challenges in this exciting field.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20959326     DOI: 10.1136/ard.2010.134684

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  89 in total

1.  Rheumatoid arthritis: Why wait? Explaining delays in seeking therapy for early arthritis.

Authors:  Fabiola Atzeni; Piercarlo Sarzi-Puttini
Journal:  Nat Rev Rheumatol       Date:  2012-03-06       Impact factor: 20.543

2.  Decreased collagen-induced arthritis severity and adaptive immunity in MKK-6-deficient mice.

Authors:  Deepa Hammaker; Katharyn Topolewski; Meghan Edgar; Toshio Yoshizawa; Akihisa Fukushima; David L Boyle; Esther Cory Burak; Robert L Sah; Gary S Firestein
Journal:  Arthritis Rheum       Date:  2012-03

Review 3.  Nanotherapeutic approaches for the treatment of rheumatoid arthritis.

Authors:  Christine T N Pham
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2011-08-11

Review 4.  Nanomedicines for chronic non-infectious arthritis: the clinician's perspective.

Authors:  Israel Rubinstein; Guy L Weinberg
Journal:  Nanomedicine       Date:  2012-05-26       Impact factor: 5.307

5.  Promotion of Inflammatory Arthritis by Interferon Regulatory Factor 5 in a Mouse Model.

Authors:  Pierre Duffau; Hanni Menn-Josephy; Carla M Cuda; Salina Dominguez; Tamar R Aprahamian; Amanda A Watkins; Kei Yasuda; Paul Monach; Robert Lafyatis; Lisa M Rice; G Kenneth Haines; Ellen M Gravallese; Rebecca Baum; Christophe Richez; Harris Perlman; Ramon G Bonegio; Ian R Rifkin
Journal:  Arthritis Rheumatol       Date:  2015-12       Impact factor: 10.995

Review 6.  The balance of tissue repair and remodeling in chronic arthritis.

Authors:  Rik Lories
Journal:  Nat Rev Rheumatol       Date:  2011-10-18       Impact factor: 20.543

Review 7.  Treatment failure in inflammatory arthritis: time to think about syndemics?

Authors:  Elena Nikiphorou; Heidi Lempp; Brandon A Kohrt
Journal:  Rheumatology (Oxford)       Date:  2019-09-01       Impact factor: 7.580

8.  Therapy: Spleen tyrosine kinase inhibitors--novel therapies for RA?

Authors:  José A Gómez-Puerta; Xavier Bosch
Journal:  Nat Rev Rheumatol       Date:  2011-02-08       Impact factor: 20.543

Review 9.  Trojan horses and guided missiles: targeted therapies in the war on arthritis.

Authors:  Mathieu Ferrari; Shimobi C Onuoha; Costantino Pitzalis
Journal:  Nat Rev Rheumatol       Date:  2015-03-03       Impact factor: 20.543

10.  Resveratrol inhibits TNF-α-induced IL-1β, MMP-3 production in human rheumatoid arthritis fibroblast-like synoviocytes via modulation of PI3kinase/Akt pathway.

Authors:  Jing Tian; Jin-wei Chen; Jie-sheng Gao; Len Li; Xi Xie
Journal:  Rheumatol Int       Date:  2013-01-18       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.